Vertex Pharmaceuticals has secured reimbursement for ALYFTREK in Australia, offering a life-changing treatment for Australians with cystic fibrosis (CF). This groundbreaking development means that approximately 3,200 Australians living with CF can now access ALYFTREK, a next-in-class treatment that targets the underlying cause of the disease. ALYFTREK is a once-daily, triple-combination CFTR modulator, simplifying treatment for patients and offering hope for a better quality of life. But here's where it gets controversial: while ALYFTREK is a significant advancement, it's just one piece of the puzzle in the complex landscape of CF treatment. And this is the part most people miss: CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands, and reproductive tract. It's caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. So, while ALYFTREK is a major breakthrough, it's essential to understand that it's not a cure-all solution. Patients and caregivers should speak with their treating healthcare professional to understand if ALYFTREK may be suitable for them. The Pharmaceutical Benefits Scheme (PBS) listing of ALYFTREK is based on global clinical trials that assessed its safety and efficacy in people with CF aged 6 years and over, supported by real-world evidence and in vitro data. Detailed information on side effects, precautions, and dosing is available in the Consumer Medicine Information (CMI). Higher levels of sweat chloride (SwCl) are associated with more severe disease. People with SwCl levels below 60 mmol/L have better lung function, fewer pulmonary exacerbations, better quality of life, and improved survival than those with higher levels of SwCl. Vertex is committed to serially innovating and improving the lives of people living with cystic fibrosis. Today, more than 95% of Australians living with cystic fibrosis now have access to a CFTR modulator, and Vertex CF medicines are treating over 75,000 people with CF across more than 60 countries on six continents. But there's still a long way to go, and Vertex is dedicated to continuing the fight against this devastating disease.
